Prabhu Mathiyalagan1, Yaxuan Liang1, David Kim1, Sol Misener1, Tina Thorne1, Christine E Kamide1, Ekaterina Klyachko1, Douglas W Losordo1, Roger J Hajjar1, Susmita Sahoo2. 1. From the Cardiovascular Research Center, Icahn School of Medicine at Mount Sinai, New York (P.M., Y.L., D.K., R.J.H., S.S.); Feinberg Cardiovascular Research Institute, Feinberg School of Medicine, Northwestern University, Chicago, IL (D.K., S.M., T.T., C.E.K., E.K., D.W.L., S.S.); and Caladrius Biosciences, New York (D.W.L.). 2. From the Cardiovascular Research Center, Icahn School of Medicine at Mount Sinai, New York (P.M., Y.L., D.K., R.J.H., S.S.); Feinberg Cardiovascular Research Institute, Feinberg School of Medicine, Northwestern University, Chicago, IL (D.K., S.M., T.T., C.E.K., E.K., D.W.L., S.S.); and Caladrius Biosciences, New York (D.W.L.). susmita.sahoo@mssm.edu.
Abstract
RATIONALE: Paracrine secretions seem to mediate therapeutic effects of human CD34+ stem cells locally transplanted in patients with myocardial and critical limb ischemia and in animal models. Earlier, we had discovered that paracrine secretion from human CD34+ cells contains proangiogenic, membrane-bound nanovesicles called exosomes (CD34Exo). OBJECTIVE: Here, we investigated the mechanisms of CD34Exo-mediated ischemic tissue repair and therapeutic angiogenesis by studying their miRNA content and uptake. METHODS AND RESULTS: When injected into mouse ischemic hindlimb tissue, CD34Exo, but not the CD34Exo-depleted conditioned media, mimicked the beneficial activity of their parent cells by improving ischemic limb perfusion, capillary density, motor function, and their amputation. CD34Exo were found to be enriched with proangiogenic miRNAs such as miR-126-3p. Knocking down miR-126-3p from CD34Exo abolished their angiogenic activity and beneficial function both in vitro and in vivo. Interestingly, injection of CD34Exo increased miR-126-3p levels in mouse ischemic limb but did not affect the endogenous synthesis of miR-126-3p, suggesting a direct transfer of stable and functional exosomal miR-126-3p. miR-126-3p enhanced angiogenesis by suppressing the expression of its known target, SPRED1, simultaneously modulating the expression of genes involved in angiogenic pathways such as VEGF (vascular endothelial growth factor), ANG1 (angiopoietin 1), ANG2 (angiopoietin 2), MMP9 (matrix metallopeptidase 9), TSP1 (thrombospondin 1), etc. Interestingly, CD34Exo, when treated to ischemic hindlimbs, were most efficiently internalized by endothelial cells relative to smooth muscle cells and fibroblasts, demonstrating a direct role of stem cell-derived exosomes on mouse endothelium at the cellular level. CONCLUSIONS: Collectively, our results have demonstrated a novel mechanism by which cell-free CD34Exo mediates ischemic tissue repair via beneficial angiogenesis. Exosome-shuttled proangiogenic miRNAs may signify amplification of stem cell function and may explain the angiogenic and therapeutic benefits associated with CD34+ stem cell therapy.
RATIONALE: Paracrine secretions seem to mediate therapeutic effects of human CD34+ stem cells locally transplanted in patients with myocardial and critical limb ischemia and in animal models. Earlier, we had discovered that paracrine secretion from human CD34+ cells contains proangiogenic, membrane-bound nanovesicles called exosomes (CD34Exo). OBJECTIVE: Here, we investigated the mechanisms of CD34Exo-mediated ischemic tissue repair and therapeutic angiogenesis by studying their miRNA content and uptake. METHODS AND RESULTS: When injected into mouse ischemic hindlimb tissue, CD34Exo, but not the CD34Exo-depleted conditioned media, mimicked the beneficial activity of their parent cells by improving ischemic limb perfusion, capillary density, motor function, and their amputation. CD34Exo were found to be enriched with proangiogenic miRNAs such as miR-126-3p. Knocking down miR-126-3p from CD34Exo abolished their angiogenic activity and beneficial function both in vitro and in vivo. Interestingly, injection of CD34Exo increased miR-126-3p levels in mouse ischemic limb but did not affect the endogenous synthesis of miR-126-3p, suggesting a direct transfer of stable and functional exosomal miR-126-3p. miR-126-3p enhanced angiogenesis by suppressing the expression of its known target, SPRED1, simultaneously modulating the expression of genes involved in angiogenic pathways such as VEGF (vascular endothelial growth factor), ANG1 (angiopoietin 1), ANG2 (angiopoietin 2), MMP9 (matrix metallopeptidase 9), TSP1 (thrombospondin 1), etc. Interestingly, CD34Exo, when treated to ischemic hindlimbs, were most efficiently internalized by endothelial cells relative to smooth muscle cells and fibroblasts, demonstrating a direct role of stem cell-derived exosomes on mouse endothelium at the cellular level. CONCLUSIONS: Collectively, our results have demonstrated a novel mechanism by which cell-free CD34Exo mediates ischemic tissue repair via beneficial angiogenesis. Exosome-shuttled proangiogenic miRNAs may signify amplification of stem cell function and may explain the angiogenic and therapeutic benefits associated with CD34+ stem cell therapy.
Authors: Douglas W Losordo; Timothy D Henry; Charles Davidson; Joon Sup Lee; Marco A Costa; Theodore Bass; Farrell Mendelsohn; F David Fortuin; Carl J Pepine; Jay H Traverse; David Amrani; Bruce M Ewenstein; Norbert Riedel; Kenneth Story; Kerry Barker; Thomas J Povsic; Robert A Harrington; Richard A Schatz Journal: Circ Res Date: 2011-07-07 Impact factor: 17.367
Authors: Héctor Peinado; Maša Alečković; Simon Lavotshkin; Irina Matei; Bruno Costa-Silva; Gema Moreno-Bueno; Marta Hergueta-Redondo; Caitlin Williams; Guillermo García-Santos; Cyrus Ghajar; Ayuko Nitadori-Hoshino; Caitlin Hoffman; Karen Badal; Benjamin A Garcia; Margaret K Callahan; Jianda Yuan; Vilma R Martins; Johan Skog; Rosandra N Kaplan; Mary S Brady; Jedd D Wolchok; Paul B Chapman; Yibin Kang; Jacqueline Bromberg; David Lyden Journal: Nat Med Date: 2012-06 Impact factor: 53.440
Authors: Adam R Williams; Konstantinos E Hatzistergos; Benjamin Addicott; Fred McCall; Decio Carvalho; Viky Suncion; Azorides R Morales; Jose Da Silva; Mark A Sussman; Alan W Heldman; Joshua M Hare Journal: Circulation Date: 2012-12-05 Impact factor: 29.690
Authors: Hadi Valadi; Karin Ekström; Apostolos Bossios; Margareta Sjöstrand; James J Lee; Jan O Lötvall Journal: Nat Cell Biol Date: 2007-05-07 Impact factor: 28.824
Authors: Philipp Jakob; Carola Doerries; Sylvie Briand; Pavani Mocharla; Nicolle Kränkel; Christian Besler; Maja Mueller; Costantina Manes; Christian Templin; Christof Baltes; Markus Rudin; Heiner Adams; Mathias Wolfrum; Georg Noll; Frank Ruschitzka; Thomas F Lüscher; Ulf Landmesser Journal: Circulation Date: 2012-11-07 Impact factor: 29.690
Authors: Marcin Wysoczynski; Asif Pathan; Joseph B Moore; Talha Farid; Jae Kim; Marjan Nasr; Yi Kang; Hong Li; Roberto Bolli Journal: Stem Cell Rev Rep Date: 2019-08 Impact factor: 5.739
Authors: Zhen Lu; Angelica Ortiz; Ioannis I Verginadis; Amy R Peck; Farima Zahedi; Christina Cho; Pengfei Yu; Rachel M DeRita; Hongru Zhang; Ryan Kubanoff; Yunguang Sun; Andrew T Yaspan; Elise Krespan; Daniel P Beiting; Enrico Radaelli; Sandra W Ryeom; J Alan Diehl; Hallgeir Rui; Constantinos Koumenis; Serge Y Fuchs Journal: J Clin Invest Date: 2021-05-17 Impact factor: 14.808